HIF-1 inhibitors as anti-cancer therapy

Science China Chemistry

Volumn 54, Issue 1, 2011, Pages 24-30

  Mooring, Suazette Reid ^a   Wang, Binghe ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

Author keywords

cancer therapy; HIF 1; hypoxia

Indexed keywords

ANGIOGENESIS; ANTI-CANCER THERAPIES; CANCER THERAPY; CELLULAR RESPONSE; HIF-1; HYPOXIA; OVER-EXPRESSION; PATIENT PROGNOSIS; SOLID TUMORS; TUMOR GROWTH;

PATHOLOGY; TRANSCRIPTION FACTORS; TUMORS;

ONCOLOGY;

EID: 79251589361     PISSN: 16747291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11426-010-4187-5     Document Type: Conference Paper

References (72)

1. J.M. Brown A.J. Giaccia 1998 The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy Cancer Res 58 1408 1416 1:STN:280:DyaK1c7ps1Ggsw%3D%3D
2. A.L. Harris 2002 Hypoxia - A key regulatory factor in tumour growth Nature Rev Cancer 2 38 47 1:CAS:528:DC%2BD38XhvF2jtL4%3D 10.1038/nrc704
3. N.C. Denko 2008 Hypoxia, HIF1 and glucose metabolism in the solid tumour Nature Rev Cancer 8 705 713 1:CAS:528:DC%2BD1cXhtVWksLfO 10.1038/nrc2468
4. J. Pouyssegur F. Dayan N.M. Mazure 2006 Hypoxia signalling in cancer and approaches to enforce tumour regression Nature 441 437 443 1:CAS:528: DC%2BD28XkvVyrsr0%3D 10.1038/nature04871
5. A.E. Greijer P. van der Groep D. Kemming A. Shvarts G.L. Semenza G.A. Meijer M.A. van de Wiel J.A. Belien P.J. van Diest E. van der Wall 2005 Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1) J Pathol 206 291 304 1:CAS:528: DC%2BD2MXmvVartLg%3D 10.1002/path.1778
6. W.G. Kaelin Jr P.J. Ratcliffe 2008 Oxygen sensing by metazoans: The central role of the HIF hydroxylase pathway Mol Cell 30 393 402 1:CAS:528:DC%2BD1cXmslOitLg%3D 10.1016/j.molcel.2008.04.009
7. S. Kaluz M. Kaluzova E.J. Stanbridge 2008 Does inhibition of degradation of hypoxia-inducible factor (HIF) alpha always lead to activation of HIF? Lessons learnt from the effect of proteasomal inhibition on HIF activity J Cell Biochem 104 536 544 1:CAS:528:DC%2BD1cXlsl2itrY%3D 10.1002/jcb.21644
8. M. Ohh C.W. Park M. Ivan M.A. Hoffman T.Y. Kim L.E. Huang N. Pavletich V. Chau W.G. Kaelin 2000 Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein Nat Cell Biol 2 423 427 1:CAS:528:DC%2BD3cXkvFCqtrk%3D 10.1038/35017054
9. R.K. Bruick S.L. McKnight 2001 A conserved family of prolyl-4- hydroxylases that modify HIF Science 294 1337 1340 1:CAS:528: DC%2BD3MXotlKmtbo%3D 10.1126/science.1066373
10. A.C.R. Epstein J.M. Gleadle L.A. McNeill K.S. Hewitson J. O'Rourke D.R. Mole M. Mukherji E. Metzen M.I. Wilson A. Dhanda Y.M. Tian N. Masson D.L. Hamilton P. Jaakkola R. Barstead J. Hodgkin P.H. Maxwell C.W. Pugh C.J. Schofield P.J. Ratcliffe 2001 C-elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation Cell 107 43 54 1:CAS:528:DC%2BD3MXnsFOntL0%3D 10.1016/S0092-8674(01)00507-4
11. P.H. Maxwell 2005 The HIF pathway in cancer Semin Cell Dev Biol 16 523 530 1:CAS:528:DC%2BD2MXpvFeltbc%3D 10.1016/j.semcdb.2005.03.001
12. C.J. Schofield P.J. Ratcliffe 2004 Oxygen sensing by HIF hydroxylases Nat Rev Mol Cell Biol 5 343 354 1:CAS:528:DC%2BD2cXjsFSltL8%3D 10.1038/nrm1366
13. Y. Tsuzuki D. Fukumura B. Oosthuyse C. Koike P. Carmeliet R.K. Jain 2000 Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1 alpha → hypoxia response element → VEGF cascade differentially regulates vascular response and growth rate in tumors Cancer Res 60 6248 6252 1:CAS:528:DC%2BD3cXos1Sksbw%3D
14. R. Bos P. van der Groep A.E. Greijer A. Shvarts S. Meijer H.M. Pinedo G.L. Semenza P.J. van Diest E. van der Wall 2003 Levels of hypoxia-Inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma Cancer 97 1573 1581 10.1002/cncr.11246
15. K.L. Talks H. Turley K.C. Gatter P.H. Maxwell C.W. Pugh P.J. Ratcliffe A.L. Harris 2000 The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages Am J Pathol 157 411 421 1:CAS:528: DC%2BD3cXlvFyru7c%3D
16. H. Zhong A.M. De Marzo E. Laughner M. Lim D.A. Hilton D. Zagzag P. Buechler W.B. Isaacs G.L. Semenza J.W. Simons 1999 Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases Cancer Res 59 5830 5835 1:CAS:528:DyaK1MXnslygsr0%3D
17. D.M. Aebersold P. Burri K.T. Beer J. Laissue V. Djonov R.H. Greiner G.L. Semenza 2001 Expression of hypoxia-inducible factor-1alpha: A novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer Cancer Res 61 2911 2916 1:CAS:528:DC%2BD3MXivFGqsr8%3D
18. P. Birner B. Gatterbauer G. Oberhuber M. Schindl K. Rössler A. Prodinger H. Budka J.A. Hainfellner 2001 Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: Its impact on prognosis and on neoangiogenesis Cancer 92 165 171 1:STN:280:DC%2BD3MzovVOquw%3D%3D 10.1002/1097-0142(20010701)92:1<165::AID-CNCR1305>3.0.CO;2-F
19. P. Birner M. Schindl A. Obermair C. Plank G. Breitenecker G. Oberhuber 2000 Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer Cancer Res 60 4693 4696 1:CAS:528:DC%2BD3cXmsFWiu70%3D
20. M.I. Koukourakis S.M. Bentzen A. Giatromanolaki G.D. Wilson F.M. Daley M.I. Saunders S. Dische E. Sivridis A.L. Harris 2006 Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial J Clin Oncol 24 727 735 1:CAS:528:DC%2BD28XitVGisLk%3D 10.1200/JCO.2005.02.7474
21. D.M. Katschinski L. Le D. Heinrich K.F. Wagner T. Hofer S.G. Schindler R.H. Wenger 2002 Heat induction of the unphosphorylated form of hypoxia-inducible factor-1 alpha is dependent on heat shock protein-90 activity J Bio Chem 277 9262 9267 1:CAS:528:DC%2BD38Xitl2ksLY%3D 10.1074/jbc.M110377200
22. J.S. Isaacs Y.J. Jung E.G. Mimnaugh A. Martinez F. Cuttitta L.M. Neckers 2002 Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway J Bio Chem 277 29936 29944 1:CAS:528: DC%2BD38XmsVKhsrg%3D 10.1074/jbc.M204733200
23. J. Zhou T. Schmid R. Frank B. Brune 2004 PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1 alpha from pVHL-independent degradation J Bio Chem 279 13506 13513 1:CAS:528:DC%2BD2cXis1emu74%3D 10.1074/jbc.M310164200
24. S. Sato N. Fujita T. Tsuruo 2000 Modulation of Akt kinase activity by binding to Hsp90 Proc Natl Acad Sci USA 97 10832 10837 1:CAS:528: DC%2BD3cXnt1ahsrY%3D 10.1073/pnas.170276797
25. Z.Q. Tian Y. Liu D. Zhang Z. Wang S.D. Dong C.W. Carreras Y. Zhou G. Rastelli D.V. Santi D.C. Myles 2004 Synthesis and biological activities of novel 17-aminogeldanamycin derivatives Bioorg Med Chem 12 5317 5329 1:CAS:528:DC%2BD2cXnvFWlu78%3D 10.1016/j.bmc.2004.07.053
26. L. Whitesell E.G. Mimnaugh B. De Costa C.E. Myers L.M. Neckers 1994 Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation Proc Natl Acad Sci USA 91 8324 8328 1:CAS:528:DyaK2cXlslKnsLw%3D 10.1073/pnas.91.18.8324
27. M.C. Rosenhagen C. Soti U. Schmidt G.M. Wochnik F.U. Hartl F. Holsboer J.C. Young T. Rein 2003 The heat shock protein 90-targeting drug cisplatin selectively inhibits steroid receptor activation Mol Endocrinol 17 1991 2001 1:CAS:528:DC%2BD3sXotFSrsLk%3D 10.1210/me.2003-0141
28. A. Dehner J. Furrer K. Richter I. Schuster J. Buchner H. Kessler 2003 NMR chemical shift perturbation study of the N-terminal domain of Hsp90 upon binding of ADP, AMP-PNP, geldanamycin, and radicicol ChemBioChem 4 870 877 1:CAS:528:DC%2BD3sXnsFymu78%3D 10.1002/cbic.200300658
29. K. Gradin J. McGuire R.H. Wenger I. Kvietikova M.L. fhitelaw R. Toftgård L. Tora M. Gassmann L. Poellinger 1996 Functional interference between hypoxia and dioxin signal transduction pathways: Competition for recruitment of the Arnt transcription factor Mol Cell Biol 16 5221 5231 1:CAS:528:DyaK28XlvFamtrY%3D
30. N.J. Mabjeesh D.E. Post M.T. Willard M.T. Willard B. Kaur E.G. Van Meir J.W. Simons H. Zhong 2002 Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells Cancer Res 62 2478 2482 1:CAS:528:DC%2BD38XjtlGrsLg%3D
31. L. Neckers 2002 Heat shock protein 90 inhibition by 17-allylamino-17- demethoxygeldanamycin: A novel therapeutic approach for treating hormone-refractory prostate cancer Clin Cancer Res 8 962 966 1:CAS:528:DC%2BD38XksVSqtbk%3D
32. L. Neckers 2003 Development of small molecule Hsp90 inhibitors: Utilizing both forward and reverse chemical genomics for drug identification Curr Med Chem 10 733 739 1:CAS:528:DC%2BD3sXjtVaju7s%3D 10.2174/0929867033457818
33. S. Modi A.T. Stopeck M.S. Gordon D. Mendelson D.B. Solit R. Bagatell W. Ma J. Wheler N. Rosen L. Norton G.F. Cropp R.G. Johnson A.L. Hannah C.A. Hudis 2007 Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study J Clin Oncol 25 5410 5417 1:CAS:528:DC%2BD1cXnvVCisQ%3D%3D 10.1200/JCO.2007.11.7960
34. Y.S. Kim S.V. Alarcon S. Lee M.J. Lee G. Giaccone L. Neckers J.B. Trepel 2009 Update on Hsp90 inhibitors in clinical trial Curr Top Med Chem 9 1479 1492 1:CAS:528:DC%2BC3cXhsFakurc%3D 10.2174/156802609789895728
35. E.R. Glaze A.L. Lambert A.C. Smith J.G. Page W.D. Johnson D.L. McCormick A.P. Brown B.S. Levine J.M. Covey M.J. Egorin J.L. Eiseman J.L. Holleran E.A. Sausville J.E. Tomaszewski 2005 Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: Potential clinical relevance Cancer Chemother Pharmacol 56 637 647 1:CAS:528:DC%2BD2MXhtVKqu7bP 10.1007/s00280-005-1000-9
36. A. Rapisarda B. Uranchimeg D.A. Scudiero M. Selby E.A. Sausville R.H. Shoemaker G. Melillo 2002 Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway Cancer Res 62 4316 4324 1:CAS:528:DC%2BD38XlvFeltbc%3D
37. A. Rapisarda B. Uranchimeg O. Sordet Y. Pommier R.H. Shoemaker G. Melillo 2004 Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: Mechanism and therapeutic implications Cancer Res 64 1475 1482 1:CAS:528:DC%2BD2cXhtleitL4%3D 10.1158/0008-5472.CAN-03-3139
38. A. Rapisarda J. Zalek M. Hollingshead T. Braunschweig B. Uranchimeg C.A. Bonomi S.D. Borgel J.P. Carter S.M. Hewitt R.H. Shoemaker G. Melillo 2004 Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts Cancer Res 64 6845 6848 1:CAS:528:DC%2BD2cXotFalsr8%3D 10.1158/0008-5472.CAN-04-2116
39. M. Creighton-Gutteridge J.H. Cardellina 2nd A.G. Stephen A. Rapisarda B. Uranchimeg K. Hite W.A. Denny R.H. Shoemaker G. Melillo 2007 Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221 Clin Cancer Res 13 1010 1018 1:CAS:528:DC%2BD2sXhsVyku7Y%3D 10.1158/1078-0432.CCR-06-2301
40. N.J. Mabjeesh D. Escuin T.M. LaVallee V.S. Pribluda G.M. Swartz M.S. Johnson M.T. Willard H. Zhong J.W. Simons P. Giannakakou 2003 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF Cancer cell 3 363 375 1:CAS:528:DC%2BD3sXjsFGgsrY%3D 10.1016/S1535-6108(03) 00077-1
41. V.S. Pribluda E.R. Gubish Jr T.M. Lavallee A. Treston G.M. Swartz S.J. Green 2000 2-Methoxyestradiol: An endogenous antiangiogenic and antiproliferative drug candidate Cancer Metastasis Rev 19 173 179 1:CAS:528:DC%2BD3MXktlSmtA%3D%3D 10.1023/A:1026543018478
42. Chua YS, Chua YL, Hagen T. Structure activity analysis of 2-methoxyestradiol analogues reveals targeting of microtubules as the major mechanism of antiproliferative and proapoptotic activity. Mol Cancer Ther, 9: 224-235
43. G. Powis W.R. Montfort 2001 Properties and biological activities of thioredoxins Annu Rev Pharmacol Toxicol 41 261 295 1:CAS:528: DC%2BD3MXjsVaqtrw%3D 10.1146/annurev.pharmtox.41.1.261
44. S.J. Welsh R.R. Williams A. Birmingham D.J. Newman D.L. Kirkpatrick G. Powis 2003 The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation Mol Cancer Ther 2 235 243 1:CAS:528:DC%2BD3sXitlyqurs%3D
45. D. Kong E.J. Park A.G. Stephen M. Calvani J.H. Cardellina A. Monks R.J. Fisher R.H. Shoemaker G. Melillo 2005 Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity Cancer Res 65 9047 9055 1:CAS:528:DC%2BD2MXhtVKiu7vN 10.1158/0008-5472.CAN-05-1235
46. M.M. Van Dyke P.B. Dervan 1984 Echinomycin binding sites on DNA Science 225 1122 1127 10.1126/science.6089341
47. D.T. Jones A.L. Harris 2006 Identification of novel small-molecule inhibitors of hypoxia-inducible factor-1 transactivation and DNA binding Mol Cancer Ther 5 2193 2202 1:CAS:528:DC%2BD28Xps1yns7o%3D 10.1158/1535-7163.MCT-05- 0443
48. Mooring SR, Jin H, Van Meir EG, Wang B. Inhibitors of HIF-1 and angiogenesis. Provisional patent file, April 2010. USA
49. Mooring SR, Jin J, Devi NS, Jabbar AA, Kaluz S, Van Meir EG, Wang B. Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway. Submit to ChemMedChem, 2010
50. Tan C, Noronha RD, Devi NS, Mooring SR, Nicolaou KC, Jabbar AA, Kaluz S, Wang B, Van Meir EG. A new scaffold of hypoxia inducible factor pathway inhibitors. Submit to Bioorg Med Chem Lett, 2010
51. S.J. Welsh R.R. Williams D.L. Kirkpatrick G. Powis 2002 PX-478, a potent inhibitor of hypoxia-inducible factor-1 (HIF-1) and antitumor agent Eur J Cancer 38 294
52. S. Welsh R. Williams L. Kirkpatrick G. Paine-Murrieta G. Powis 2004 Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha Mol Cancer Thers 3 233 244 1:CAS:528: DC%2BD2cXitFCnsrk%3D
53. M.Y. Koh T. Spivak-Kroizman S. Venturini S. Welsh R.R. Williams D.L. Kirkpatrick G. Powis 2008 Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha Mol Cancer Thers 7 90 100 1:CAS:528:DC%2BD1cXmsVynsA%3D%3D 10.1158/1535-7163.MCT-07-0463
54. S.T. Palayoor J.B. Mitchell D. Cerna W. Degraff M. John-Aryankalayil C.N. Coleman 2008 PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells Int J Cancer 123 2430 2437 1:CAS:528:DC%2BD1cXhtleiurfJ 10.1002/ijc.23807
55. L.M. Greenberger I.D. Horak D. Filpula P. Sapra M. Westergaard H.F. Frydenlund C. Albaek H. Schrøder H. Rum 2008 A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth Mol Cancer Ther 7 3598 3608 1:CAS:528:DC%2BD1cXhtlGgs77K 10.1158/1535-7163.MCT-08-0510
56. G.L. Semenza 2007 Evaluation of HIF-1 inhibitors as anticancer agents Drug Discov Today 12 853 859 1:CAS:528:DC%2BD2sXhtFKit77O 10.1016/j.drudis.2007. 08.006
57. B. Vester J. Wengel 2004 LNA (locked nucleic acid): High-affinity targeting of complementary RNA and DNA Biochemistry 43 13233 13241 1:CAS:528:DC%2BD2cXotVCjt78%3D 10.1021/bi0485732
58. E.W. Newcomb M.A. Ali T. Schnee L. Lan Y. Lukyanov M. Fowkes D.C. Miller D. Zagzag 2005 Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1 alpha expression in human glioma cells by a proteasome-independent pathway: Implications for in vivo therapy Neuro-Oncology 7 225 235 1:CAS:528:DC%2BD2MXos1Cmtr4%3D 10.1215/S1152851704000997
59. S. Sekita K. Yoshihira S. Natori S. Udagawa T. Muroi Y. Sugiyama H. Kurata M. Umeda 1981 Mycotoxin production by Chaetomium spp. and related fungi Can J Microbiol 27 766 772 1:CAS:528:DyaL3MXmtFOgtbo%3D 10.1139/m81-119
60. D. Brewer J.M. Duncan W.A. Jerram C.K. Leach S. Safe A. Taylor L.C. Vining R.M. Archibald R.G. Stevenson C.J. Mirocha C.M. Christensen 1972 Ovine ill-thrift in Nova Scotia. 5. The production and toxicology of chetomin, a metabolite of chaetomium spp Can J Microbiol 18 1129 1137 1:CAS:528: DyaE38XksF2qu74%3D 10.1139/m72-174
61. P. Carrero K. Okamoto P. Coumailleau S. O'Brien H. Tanaka L. Poellinger 2000 Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1alpha Mol Cell Biol 20 402 415 1:CAS:528:DC%2BD3cXlt1ak 10.1128/MCB.20.1.402-415.2000
62. M. Ema K. Hirota J. Mimura H. Abe J. Yodoi K. Sogawa L. Poellinger Y. Fujii-Kuriyama 1999 Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300 EMBO J 18 1905 1914 1:CAS:528:DyaK1MXivVyks7w%3D 10.1093/emboj/18.7.1905
63. A.L. Kung S. Wang J.M. Klco W.G. Kaelin D.M. Livingston 2000 Suppression of tumor growth through disruption of hypoxia-inducible transcription Nat Med 6 1335 1340 1:CAS:528:DC%2BD3cXosl2hsrk%3D 10.1038/82146
64. Z. Arany L.E. Huang R. Eckner S. Bhattacharya C. Jiang M.A. Goldberg H.F. Bunn D.M. Livingston 1996 An essential role for p300/CBP in the cellular response to hypoxia Proc Natl Acad Sci USA 93 12969 12973 1:CAS:528: DyaK28XmvV2ksL0%3D 10.1073/pnas.93.23.12969
65. A.L. Kung S.D. Zabludoff D.S. France S.J. Freedman E.A. Tanner A. Vieira S. Cornell-Kennon J. Lee B. Wang J. Wang K. Memmert H.U. Naegeli F. Petersen M.J. Eck K.W. Bair A.W. Wood D.M. Livingston 2004 Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway Cancer cell 6 33 43 1:CAS:528:DC%2BD2cXmtlKnt7s%3D 10.1016/j.ccr.2004.06.009
66. K.M. Cook S.T. Hilton J. Mecinovic W.B. Motherwell W.D. Figg C.J. Schofield 2009 Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1alpha (HIF-1alpha) and p300 by a zinc ejection mechanism J Biolog Chem 284 26831 26838 1:CAS:528:DC%2BD1MXhtFCgs7fM 10.1074/jbc.M109.009498
67. J.A. Loo T.P. Holler J. Sanchez R. Gogliotti L. Maloney M.D. Reily 1996 Biophysical characterization of zinc ejection from HIV nucleocapsid protein by anti-HIV 2,2′-dithiobis[benzamides] and benzisothiazolones J Med Chem 39 4313 4320 1:CAS:528:DyaK28Xlslajtbs%3D 10.1021/jm960253w
68. M.I. Koukourakis C. Simopoulos A. Polychronidis S. Perente S. Botaitis A. Giatromanolaki E. Sivridis 2003 The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIFI alpha/VEGF pre-treatment status? Anticancer Res 23 1673 1680 1:CAS:528:DC%2BD3sXltlKisr8%3D
69. L. Ellis H. Hammers R. Pili 2009 Targeting tumor angiogenesis with histone deacetylase inhibitors Cancer Lett 280 145 153 1:CAS:528: DC%2BD1MXmsF2jt74%3D 10.1016/j.canlet.2008.11.012
70. Y.M. Lee S.H. Kim H.S. Kim M. Jin Son H. Nakajima H. Jeong Kwon K.W. Kim 2003 Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1 alpha activity Biochem Biophys Res Co 300 241 246 1:CAS:528:DC%2BD38Xps1Wgsb8%3D 10.1016/S0006-291X(02)02787-0
71. E.J. Yeo J.H. Ryu Y.S. Cho Y.S. Chun L.E. Huang M.S. Kim J.W. Park 2006 Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1 Blood 107 916 923 1:CAS:528: DC%2BD28Xht1Onsbo%3D 10.1182/blood-2005-06-2564
72. E.J. Park D. Kong R. Fisher J. Cardellina R.H. Shoemaker G. Melillo 2006 Targeting the PAS-A domain of HIF-1 alpha for development of small molecule inhibitors of HIF-1 Cell Cycle 5 1847 1853 1:CAS:528:DC%2BD28Xht1Gnt7vL 10.4161/cc.5.16.3019